Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

(2009) S A Stoch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7

(2008) Kim Henriksen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

(2008) Jacques Yves Gauthier et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Bone density, strength, and formation in adult cathepsin K (−/−) mice

(2008) B. Pennypacker et al.   BONE

Characterization of the Bone Phenotype in ClC-7-Deficient Mice

(2008) Anita Vibsig Neutzsky-Wulff et al.   CALCIFIED TISSUE INTERNATIONAL

Ion Transporters Involved in Acidification of the Resorption Lacuna in Osteoclasts

(2008) Kim Henriksen et al.   CALCIFIED TISSUE INTERNATIONAL

Drug-induced morphea: Report of a case induced by balicatib and review of the literature

(2008) Anna Peroni et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY